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Stimulation of vasopressin (V,) receptors of rat aortic smooth muscle cells (A-10, ATCC CRL 1476) results in the hydro- 
lysis of phosphatidylinositol4,5-bisphosphate (PIP,) to inositol 1,4,5_trisphosphate (IP,) and diacylglycerol (DAG) with 
the mobilization of intracellular calcium. When A-10 cells are exposed to arginine vasopressin (AVP), there is an increase 
in the level of c-fos oncoprotein. The extent of induction of c-fos oncoprotein depends on both the time of exposure 
of the cells to AVP, reaching a maximum at 60 min after which there is a slow decline, and the concentration of AVP 
used, with an approximate EC,, of 1 nM which corresponds well with the Kd of vasopressin binding to these receptors. 
This vasopressin-mediated increase in c-fos protein level is inhibited by a V,/V, antagonist (SKF 101498) suggesting that 
this is a receptor-mediated vent. In addition dDAVP, a V, selective agonist, is much less effective than AVP in inducing 
c-fos protein suggesting that AVP mediates its effect via V, receptors. Desensitization of vasopressin receptors by pro- 
longed exposure to AVP resulted in no additional induction of c-fos protein level in response to second challenge of 
AVP. In addition to AVP, phorbol dibutyrate (PDBu), an activator of protein kinase C (PKC), also stimulates the accu- 
mulation of c-fos protein although to a lesser extent han AVP. The above data suggest hat c-fos protein levels in smooth 
muscle cells are regulated by AVP and the hormonal effect may be mediated through PI turnover and DAG, IP, and 
Ca*+ signals. 
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1. INTRODUCTION 
Cellular oncogenes have been implicated in the 
control of normal cell proliferation. Mutation or 
abnormal or inappropriate expression of these on- 
cogenes can adversely affect the normal control of 
cell growth and/or differentiation [l]. c-myc and 
c-fos belong to a class of proto-oncogenes whose 
products are localized in the nucleus, although 
their exact function is unknown. 
Rapid changes in c-fos, c-myc and actin mRNA 
levels following addition of serum to quiescent 
cultures of smooth muscle cells suggest hat these 
genes may be involved in the onset of smooth mus- 
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cle cell proliferation. Similar observations have 
been reported in other cell systems [2-71. Abnor- 
mal proliferation of smooth muscle cells has been 
implicated in the development of atherosclerosis 
and Benditt et al. [7] have reported that viral infec- 
tion of smooth muscle cells can also result in these 
lesions. 
Our laboratory has been interested in the signal 
transduction pathways activated by vasopressin 
receptors. In an attempt to understand the rela- 
tionship between vasopressin receptors and cell 
growth and proliferation we have used a model 
system A-10 (ATCC CRL 1476), a smooth muscle 
cell line derived from rat thoracic aorta that 
displays a high density of vasopressin (VI) recep- 
tors. These vasopressin receptors mediate vascular 
contraction by interacting with phosphoinositide 
specific phospholipase C (PI-PLC) generating two 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/89/$3.50 0 1989 Federation of European Biochemical Societies 61 
Volume 245, number 1,2 FEBS LETTERS March 1989 
intracellular second messengers, IP3 and 
diacylglycerol. While IPs releases intracellular 
calcium, DAG activates protein kinase C which 
phosphorylates key proteins resulting in regulation 
of cellular functions. The data presented here 
demonstrate that AVP acting through Vi receptors 
increases c-fos protein levels. 
2. MATERIALS AND METHODS 
AVP and dDAVP were from Bachem, California. Vr/Vz an- 
tagonist SK&F 101498 was synthesized in SK&F Laboratories. 
Phorbol dibutyrate and 4cY-phorbol didecanoate were from 
Sigma, St. Louis. All other chemicals were of reagent grade. 
The antibodies have been decsribed [8]. 
2.1. Cell culture 
Rat aortic smooth muscle cells (AIO) were obtained from the 
American Type Culture Collection and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) plus 20% fetal calf serum 
(FCS) in 95% air/S% CO2 [9]. All experiments were carried out 
with cells passaged for no more than 4 months. Culture flasks 
(Falcon T-150) were inoculated with 1.5 x lo6 cells, which were 
cultured in 20 ml medium. Experiments were carried out after 
3 days unless otherwise mentioned. 
2.2. Treatment of cells with vasopressin andpreparation of cell 
lysates for ELBA 
Cells in monolayers were washed 2 x with 20 ml DPBS 
(Dulbecco’s phosphate buffered saline) at 37°C and then in- 
cubated in 10 ml DPBS with the indicated concentrations of test 
compounds for the times indicated at 37°C. At the end of the 
incubation, DPBS was removed and the cells were washed with 
ice cold DPBS, removed with a scraper in ice cold DPBS and 
collected by centrifugation. The cell lysate for the ELISA was 
prepared as described [lo]. Immediately before use, samples 
were thawed and insoluble materials were removed by cen- 
trifugation at 14000 x g for 2 min. 
2.3. Absorption and detection of bound fos proteins 
The absorption of a fos 5 antibody and capture of the c-fos 
protein from the cell lysates were done following the procedure 
of Moore et al. [lO,ll]. Bound fos proteins were recognized by 
incubation with 100 pi/well of antibody/alkaline phosphatase 
conjugate (a fos 1-AP) diluted in TMT [4% non-fat milk 
powder, 0.5% Tween in TBS (Tris buffered saline, pH 8.0)] and 
incubated on a rocker for 1 h at room temperature. The incuba- 
tion was terminated by washing the wells thoroughly with TBS 
(6 x with 200 ,!Uwell). 
Bound alkaline phosphatase was detected with the ELISA 
amplification system (BRL). The design of the system has been 
described as has its use in ELlSAs for myc oncoproteins 
[lo, 111. In the present assay the wells were incubated for 30 min 
at room temperature with 100 pl of ‘substrate solution’, follow- 
ed by 30 min with 100 pl of ‘amplifier solution’. The reactions 
were stopped by addition of 50 ~1 of 0.5 M HCl and the absor- 
bance (OD492) determined using a conventional automated 
plate-reader (Titertek). 
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2.4. Desensitization of A-IO cells in response to A VP 
The cells in T-150 flasks were treated with 1 PM AVP for 
30 min or 2 h at 37°C. At the end of the pretreatment the 
medium was removed, fresh medium added and the incubation 
continued for another 2 h to wash off any bound AVP. At the 
end of this incubation, the medium was removed and the cells 
were washed with DPBS 4 x (10 ml each time) and processed 
as described above. 
Each experiment was performed in quadruplicate and 
repeated at least twice. The data presented are from one 
representative xperiment. 
3. RESULTS AND DISCUSSION 
Incubation of rat thoracic aortic smooth muscle 
cells (AIO) with 1 PM AVP elicited a time- 
dependent increase in c-fos protein in these cells 
(fig.]). Maximal stimulation was observed at 
60 min after which the level started to decline slow- 
ly. Tumor promoting phorbol ester (PDBu), an ac- 
tivator of protein kinase C, also caused a 
time-dependent increase in c-fos protein although 
to a lesser extent than AVP (fig.1). 
4cz-12,13-didecanoate (aPDD), which does not ac- 
tivate protein kinase C, did not induce an increase 
in c-fos protein (fig.]). 
The AVP-mediated increase in c-fos protein 
level was dependent on the concentration of AVP 
used (fig.2). Even at concentrations as low as 
0.1 nM, there was a significant increase in c-fos 
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Fig.1. Time course of c-fos protein appearance in response to 
AVP and phorbol dibutyrate: smooth muscle cells in T-150 
flasks were treated with the medium above, 1 PM AVP or 1 PM 
PDBu for indicated time periods and processed as explained in 
section 2. Basal (0); AVP (A); PDBu (0) and (rPDD (x). The 
data presented are the mean of four independent 
determinations from one experiment with < 10% variation 
between the values. The experiment was repeated with similar 
results. 
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Fig.2. C-fos protein appearance in response to increasing 
concentrations of AVP: A-10 cells in T-150 flasks were 
incubated with medium alone or increasing concentrations of 
AVP for 1 h. At the end of incubation, the cells were washed 
and c-fos protein levels were quantitated as explained in section 
2. The data presented are the mean of four independent 
determinations from one experiment with <5% variation 
between the values. The experiment was repeated with similar 
results. 
protein levels. The concentration of AVP required 
to increase the protein level half-maximally (1 r&I) 
corresponds well with both the kDa of this hor- 
mone for binding to these receptors [12] and the 
concentration required to half-maximally stim- 
ulate inositol phosphates accumulation in these 
cells [13], suggesting that both processes may be 
mediated by the same receptors. To further con- 
firm that this is a receptor-mediated event, we 
studied the effects of SK&F 101498, a Vi/V2 an- 
tagonist on c-fos protein levels. While SK&F 
101498 had no effect on c-fos protein levels by 
itself, it markedly inhibited the stimulation 
mediated by AVP (table 1). Furthermore, dDAVP, 
a VZ selective agonist, was much less effective than 
AVP in stimulating c-fos protein, suggesting that 
the effects of AVP are mediated by Vr receptors 
(not shown). 
We also studied the effect of regulating 
vasopressin receptor response on c-fos protein. 
One of the mechanisms of regulating receptors is 
desensitization. Prolonged treatment of these cells 
with AVP results in an attenuation of both inositol 
phosphates accumulation and intracellular calcium 
release in response to a second challenge of AVP 
(submitted). These reduced responses are accom- 
panied by a loss in cell surface receptors for 
vasopressin. Under the conditions where the ac- 
cumulation of inositol phosphate was attenuated, 
there was no c-fos protein induction in response to 
AVP in desensitized cells (table 2). The basal levels 
of c-fos protein in the desensitized cells was greater 
than that in control cells (208 + 5.5 vs 51 +- 5.1). 
This is attributable to induction of c-fos protein by 
the initial exposure to AVP (cf. fig. 1, 120 min data 
point). Note that whereas the control cells were 
fully responsive to AVP (396 * 25), desensitized 
cells were not responsive to a second challenge with 
AVP (173 f 19). This time course (2 h pretreat- 
ment) compares very well with desensitization of 
inositol phosphate turnover (submitted). 
Taken together the above data suggest hat in 
smooth muscle cells, vasopressin acting through VI 
receptors induces c-fos protein expression in a 
time- and dose-dependent manner which is blocked 
by a Vi/V2 antagonist. Desensitization of the 
vasopressin receptors by prolonged treatment with 
AVP results in an attenuated response to further 
stimulation, supporting the relationship between 
AVP receptors and c-fos protein levels. In addition 
Table 1 
Effect of Vr/Vz antagonist (SK&F 101498) on vasopressin (AVP)-mediated c-fos 
protein expression in vascular smooth muscle cells (A-10) 
Time of exposure OD 492 
(min) 
Basal SK&F 101498 AVP SK&F 101498 +
AVP 
60 0.21 f 0.053 0.18 & 0.052 3.73 zt 0.087 0.91 zt 0.087 
120 0.32 jz 0.037 0.18 + 0.046 2.79 + 0.028 1.02 f 0.076 
A-10 cells were incubated with medium alone (basal), 1 ,uM each of SK&F 101498 
or AVP or both together for 60 min and 120 min. At the end of incubation, the 
cells were washed and assayed for c-fos protein 
63 
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Table 2 
Effect of vasopressin-induced desensitization on c-fos protein 
expression in A-10 cells 
Condition OD 492 
Basal AVP 
Control 0.51 f 0.051 3.96 f 0.25 
Desensitized 2.08 f 0.055 1.73 * 0.19 
A-10 cells were pretreated with medium alone (control) or 1 ,uM 
AVP (desensitized) for 2 h at 37°C. At the end of the 
pretreatment, the medium was removed, fresh medium was 
added and the incubation continued for another 2 h to reverse 
any bound AVP from the receptors. At the end of second 
incubation, the cells were washed and challenged with medium 
alone (basal) or 1 ,uM AVP for 60 min at 37°C and assayed for 
c-fos protein expression 
to AVP, tumor promoters such as PDBu also 
stimulate c-fos protein levels although to a much 
lesser extent. This suggests that mechanism(s) 
other than PKC activation may also be involved in 
the increase of c-fos protein level. At present it is 
not known whether the AVP-induced increase in c- 
fos protein levels is due to activation of transcrip- 
tion, translation or stabilization of the protein, or 
a combination of these factors. In contrast to 
serum-stimulation of quiescent fibroblasts, where 
both c-fos and c-myc are induced, in smooth mus- 
cle cells activation of vasopressin receptors results 
in induction of c-fos protein without any change in 
c-myc protein levels (unpublished). 
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